Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
[google_news title=”” keyword=”colorectal cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- What is colorectal cancer? Signs, symptoms, risks and more of the global health concernon February 23, 2024 at 4:57 am
Explore the complexities of colorectal cancer, from signs and symptoms to treatment options, empowering individuals with crucial knowledge for early detection and management.
- 90 Day Fiancé: What Happened To Mary DeNuccio? (Her Colon Cancer Claim Explained)on February 22, 2024 at 8:36 pm
"Please God guide me I don't wanna die," Mary DeNuccio (Demasu-ay) wrote in her Instagram story as she told 90 Day Fiancé fans she had colon cancer.
- HealthyU seminar to teach about colon canceron February 22, 2024 at 10:00 am
A HealthyU seminar at Northwest Health next month will cover colon cancer and why it’s becoming more prevalent among adults. Board-certified colorectal surgeon D. Owen Young will deliver a talk ...
- '90 Day Fiancé's Mary Denucciõ Denies Colon Cancer After Viral Fundraiseron February 22, 2024 at 9:20 am
Fiancé: The Other Way 's Mary Denucciõ and her husband Brandan —who spell their last name both Denucciõ and De Nucciõ on their social media pages—announced that she was diagnosed with colon cancer and ...
- Mary DeNuccio used fundraising money despite no colon cancer diagnosison February 22, 2024 at 6:30 am
If you thought the saga of Mary DeNuccio claiming to have colon cancer was over, boy, do we have news for you. Amid fierce backlash towards both Mary and her husband, Brandan DeNuccio, after it ...
- '90 Day Fiancé's Mary Admits She Doesn't Have Colon Cancer as Brandan's Fundraising Page Gets Deletedon February 21, 2024 at 3:49 pm
Mary from 90 Day Fiancé: The Other Way is apologizing after alarming fans last week when she said she was diagnosed with colon cancer. She now explains it was all a big mixup on her part after she ...
- Gut bacteria linked to colorectal cancer in young peopleon February 21, 2024 at 11:09 am
Colorectal cancer most often affects people over age 50, but it's on the rise in younger people, who are rarely offered screening to catch these cancers early. Now, a new study hints that microbes ...
- Does 90 Day Fiance’s Mary Have Colon Cancer? Updates on the Mystery Surrounding Her Healthon February 21, 2024 at 4:29 am
The mystery surrounding Mary’s health began when she shared via Instagram Stories on February 16, 2024, that she had received a colon cancer diagnosis. “This is the most scary moment in my life ...
- Colon cancer is killing more younger people than ever. A cancer expert shares 4 easy ways to lower your risk.on February 19, 2024 at 8:55 am
With more people under 50 dying from colon cancer, an expert shares how to reduce the risk of developing the colorectal disease.
- Best At-Home Colon Cancer Tests Of 2024on February 14, 2024 at 7:35 am
To find the best at-home colon cancer tests of 2024, we looked at an array of at-home tests and analyzed data points such as manufacturer cost, third-party cost, average time to get results, if ...
via Google News and Bing News